Johnson Noah Ray, Kruger Maritza, Goetsch Kyle Peter, Zilla Peter, Bezuidenhout Deon, Wang Yadong, Davies Neil Hamer
Cardiovascular Research Unit, MRC IUCHRU, Chris Barnard Division of Cardiothoracic Surgery, Department of Health Sciences, University of Cape Town, Cape Town, South Africa.
ACS Biomater Sci Eng. 2015 Sep 14;1(9):753-759. doi: 10.1021/acsbiomaterials.5b00077. Epub 2015 Aug 10.
Regenerative therapies to improve prognosis after heart attack and mitigate the onset of heart failure are urgently needed. To this end, we developed a bioactive therapy of sustained release of the morphogen Sonic hedgehog (Shh) and the anti-inflammatory cytokine interleukin-10 (IL-10) from a coacervate delivery vehicle. This is combined with a structural therapy consisting of a biodegradable polyethylene glycol (PEG) hydrogel, harnessing the benefits of both components. Upon injection into the hearts of rats after heart attack, we found that each component synergistically improved the benefit of the other. Furthermore, their combination was critical to preserve heart function. These findings indicate that, when combined, growth factor delivery and an injectable hydrogel represent a promising therapeutic approach for treatment after heart attack.
迫切需要再生疗法来改善心脏病发作后的预后并减轻心力衰竭的发作。为此，我们开发了一种生物活性疗法，可从凝聚层递送载体中持续释放形态发生素 Sonic hedgehog（Shh）和抗炎细胞因子白细胞介素-10（IL-10）。这与由可生物降解的聚乙二醇（PEG）水凝胶组成的结构疗法相结合，利用了两种成分的优点。在心脏病发作后注射到大鼠心脏中后，我们发现每个成分都能协同提高另一个成分的益处。此外，它们的组合对于维持心脏功能至关重要。这些发现表明，生长因子递送和可注射水凝胶相结合代表了一种有前途的心脏病发作后治疗方法。
